LLLin Li

Lin Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lin Li has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures from Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers

    by Remi Klotz, Amal Thomas, Teng Teng, Sung Min Han, Oihana Iriondo, Lin Li, Sara Restrepo-Vassalli, Alan Wang, Negeen Izadian, Matthew MacKay, et al.

    File includes supplementary figures S1 to S5

  • Open Access

    Development of a Novel Reference Material for Tumor Mutational Burden Measurement Based on CRISPR/Cas9 Technology

    by Rongxue Peng, Guigao Lin, Lin Li, Jinming Li

    As a biomarker that affects treatment decisions of immune checkpoint inhibitors, the accuracy, reliability, and comparability of tumor mutational burden (TMB) estimation is of paramount importance. To improve the consistency and reliability of these tests, qualified reference materials providing ground-truth data are crucial. In this study, we developed a set of formalin-fixed and paraffin-embedded (FFPE) samples with different TMB values as the novel reference materials for TMB estimation. By introducing several clinically relevant variants in MutS Homolog 2 (MSH2) gene and DNA polymerase epsilon (POLE) gene into human cell lines using CRISPR/Cas9 technology, we first constructed four typical cell lines which verified with hypermutator or ultramutator phenotype. Followed by cell mixing and paraffin embedding, the novel FFPE samples were prepared. It was confirmed that our novel FFPE samples have sufficient quantity of cells, high reproducibility, and they can provide matched wild type sample as the genetic background. The double-platform whole exome sequencing validation showed that our FFPE samples were also highly flexible as they containing different TMB values spanning a clinically relevant range (2.0–106.1 mut/Mb). Without limitations on production and TMB values, our novel FFPE samples based on CRISPR/Cas9 editing are suitable as candidate reference materials. From a practical point of view, these samples can be used for the validation, verification, internal quality control, and proficiency testing of TMB assessment.


  • Open Access

    Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer

    by Libo Si, Hui Tian, Weiming Yue, Lin Li, Shuhai Li, Cun Gao, Lei Qi

    MicroRNAs (miRNAs/miRs) are a class of small, highly conserved non‑coding RNAs that can serve either oncogenic or tumor‑suppressive roles in a wide variety of tumors. miR‑200c is a member of the miR‑200 family whose specific role in non‑small cell lung cancer (NSCLC) has not yet been elucidated. The purpose of the present study was to detect the expression level of miR‑200c in NSCLC, and to analyze its association with clinicopathological factors and patient prognosis. The present study determined the expression levels of miR‑200c in 110 tumor samples collected from patients diagnosed with NSCLC who underwent complete tumor resection with regional lymph node dissection, as assessed by reverse transcription‑quantitative polymerase chain reaction. The association between the expression level of miR‑200c and clinicopathological features and patient prognosis was also analyzed. The results showed that miR‑200c overexpression was detected in 66 of the 110 cases and was significantly associated with positive lymph node metastasis (P<0.001). Univariate survival analysis demonstrated that high miR‑200c expression, positive lymph node metastasis and advanced Tumor‑Node‑Metastasis (TNM) classification stage significantly predicted decreased 5‑year disease‑free survival rates (all P<0.05) and poor 5‑year overall survival rates (all P<0.01), respectively. The results of multivariate Cox regression analysis showed that TNM stage and miR‑200c expression retained its significance as an independent prognostic factor for unfavorable 5‑year disease‑free survival rates (P<0.05) and poor 5‑year overall survival rates (P<0.01). The present findings suggest that miR‑200c overexpression is significantly associated with poor survival rates in NSCLC and that miR‑200c could play an oncogenic role. miR‑200c may have clinical potential as a promising prognostic predictor for patients with NSCLC.


  • Daidzein-metabolizing phenotypes in relation to serum hormones and sex hormone binding globulin, and urinary estrogen metabolites in premenopausal women in the United States

    by Charlotte Atkinson, Katherine M. Newton, Frank Z. Stanczyk, Kim C. Westerlind, Lin Li, Johanna W. Lampe

    Blood and urine concentrations of hormones are implicated in the etiology of some cancers. Small studies have assessed relationships between production of the daidzein metabolites equol and O-desmethylangolensin (ODMA) and hormones, but findings are unclear. We evaluated relationships between daidzein-metabolizing phenotypes and follicular phase concentrations of estrogens, androgens, sex hormone binding globulin (SHBG), and urinary estrogen metabolites in premenopausal women.